Avanzarx Pharmaceutical Holdings, LLC

Name of License: 
Avanzarx Pharmaceutical Holdings, LLC
By the: 
Department of Veterans Affairs, Office of Research and Development (VA)
On: 
Jul 22, 2021
Summary 

VA intends to offer Avanzarx Pharmaceutical Holdings, LLC an exclusive license to technology called "Treatment of Pulmonary Fibrosis using NEU1 Salidase Inhibitors" by Goldblum et al., VA ID 2019-175

Tech Name: 
Treatment of Pulmonary Fibrosis using NEU1 Salidase Inhibitors
Action: 
Intent
Dates: 
July 22, 2021 through August 6, 2021
Address: 
U.S. Department of Veterans Affairs Technology Transfer Program (14RDTT) 810 Vermont Ave, NW Washington, DC 20420
For further information contact 

David Marks
U.S. Department of Veterans Affairs
Technology Transfer Program (14RDTT)
810 Vermont Ave, NW
Washington, DC 20420
Office: 202-443-5609
email: david.marks2@va.gov

Upload PDF: 
PDF icon 2021-7-22_notice_for_exclusive_license_agreement_with_avanzarx_pharmaceuticals_va_id_2019-175.pdf